The demand for Lipid-Lowering Agents in Iran has been steadily increasing over the past few years.
Customer preferences: Customers in Iran are increasingly concerned about their heart health and are turning to Lipid-Lowering Agents to manage their cholesterol levels. This is due to a growing awareness of the health risks associated with high cholesterol levels, including heart disease and stroke. Additionally, the aging population in Iran is more susceptible to these health concerns, driving the demand for Lipid-Lowering Agents even higher.
Trends in the market: The Lipid-Lowering Agents market in Iran is dominated by statins, which account for the majority of sales in this category. However, there has been a shift towards more affordable generic versions of these drugs, as many Iranians cannot afford the high cost of branded options. This trend is expected to continue as the government pushes for more affordable healthcare options for its citizens.
Local special circumstances: The Iranian government has been actively promoting the use of generic drugs as a way to reduce healthcare costs for its citizens. This has led to an increase in the availability of generic Lipid-Lowering Agents, which has in turn driven down prices. However, there are concerns about the quality of some of these generic drugs, as they may not be as effective as their branded counterparts.
Underlying macroeconomic factors: The Iranian economy has been struggling in recent years due to a combination of factors, including international sanctions and political instability. This has led to a depreciation of the Iranian rial and rising inflation, which has made it difficult for many Iranians to afford healthcare. As a result, there has been a growing demand for more affordable Lipid-Lowering Agents, which has driven the shift towards generic options.Overall, the Lipid-Lowering Agents market in Iran is expected to continue to grow as the population ages and more people become aware of the health risks associated with high cholesterol levels. However, the market will likely continue to be dominated by generic options due to the high cost of branded drugs and the government's push for more affordable healthcare options.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
